Tecoro Bio Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 14

Tecoro Bio General Information

Description

Developer of biopharmaceutical products designed for the treatment of dermatologic diseases. The company develops small-molecule drug candidates utilizing selective inhibitors and thyromimetics for topical administration, enabling the healthcare sector to provide targeted therapies for skin disorders with minimal systemic exposure.

Contact Information

Website
www.tkskin.com
Formerly Known As
Jiaxing Tecoro Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 1401, Building 2, Number 18, Section 2
  • Bio-City Middle Road, Shuangliu District
  • Chengdu, Sichuan 610219
  • China
+86 028
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Room 1401, Building 2, Number 18, Section 2
  • Bio-City Middle Road, Shuangliu District
  • Chengdu, Sichuan 610219
  • China
+86 028

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tecoro Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 15-Jan-2024 Completed Generating Revenue
8. Later Stage VC 08-May-2023 Completed Generating Revenue
7. Later Stage VC (Series A1) 11-Oct-2022 Completed Generating Revenue
6. Secondary Transaction - Private 27-Oct-2021 Completed Generating Revenue
5. Later Stage VC (Series A) 07-Apr-2021 Completed Generating Revenue
4. Early Stage VC 18-Sep-2018 Completed Generating Revenue
3. Secondary Transaction - Private 26-Jul-2018 Completed Generating Revenue
2. Accelerator/Incubator 29-Nov-2016 Completed Generating Revenue
1. Early Stage VC 20-May-2016 Completed Generating Revenue
To view Tecoro Bio’s complete valuation and funding history, request access »

Tecoro Bio Patents

Tecoro Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4745127-A1 Pyrimidinamine nuak inhibitor as well as preparation method therefor and use thereof Pending 13-Jul-2023
EP-4745131-A1 Pyrimidinamine nuak inhibitor as well as preparation method therefor and use thereof Pending 13-Jul-2023
WO-2025011444-A1 Pyrimidinamine nuak inhibitor as well as preparation method therefor and use thereof Inactive 13-Jul-2023
WO-2025011446-A1 Pyrimidinamine nuak inhibitor as well as preparation method therefor and use thereof Inactive 13-Jul-2023
EP-4745132-A1 Pyrimidinamine nuak inhibitor, and preparation method therefor and use thereof Pending 13-Jul-2023 C07D401/14
To view Tecoro Bio’s complete patent history, request access »

Tecoro Bio Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Viva Ventures Biotech Group Venture Capital Minority
Zoo Capital Venture Capital Minority
Hiway Capital Venture Capital Minority
Chengdu Bio-Town Investment Government Minority
Orinno Capital Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Tecoro Bio FAQs

  • When was Tecoro Bio founded?

    Tecoro Bio was founded in 2014.

  • Where is Tecoro Bio headquartered?

    Tecoro Bio is headquartered in Chengdu, China.

  • What industry is Tecoro Bio in?

    Tecoro Bio’s primary industry is Drug Discovery.

  • Is Tecoro Bio a private or public company?

    Tecoro Bio is a Private company.

  • What is Tecoro Bio’s current revenue?

    The current revenue for Tecoro Bio is .

  • How much funding has Tecoro Bio raised over time?

    Tecoro Bio has raised $15.4M.

  • Who are Tecoro Bio’s investors?

    Viva Ventures Biotech Group, Zoo Capital, Hiway Capital, Chengdu Bio-Town Investment, and Orinno Capital are 5 of 14 investors who have invested in Tecoro Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process